Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $4.36 in the last session, down -0.91% from day before closing price of $4.4. In other words, the price has decreased by -$0.91 from its previous closing price. On the day, 25.9 million shares were traded. RXRX stock price reached its highest trading level at $4.395 during the session, while it also had its lowest trading level at $4.18.
Ratios:
We take a closer look at RXRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.60 and its Current Ratio is at 4.60. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 22 ’25 when Najat Khan bought 124,403 shares for $4.41 per share.
Gibson Christopher sold 40,000 shares of RXRX for $180,000 on Dec 19 ’25. The Chief Executive Officer now owns 913,839 shares after completing the transaction at $4.50 per share. On Dec 19 ’25, another insider, Gibson Christopher, who serves as the Officer of the company, bought 40,000 shares for $4.50 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2272705792 and an Enterprise Value of 1695243648. For the stock, the TTM Price-to-Sale (P/S) ratio is 51.94 while its Price-to-Book (P/B) ratio in mrq is 2.05. Its current Enterprise Value per Revenue stands at 38.803 whereas that against EBITDA is -2.658.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.94, which has changed by -0.42558748 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -11.49%, while the 200-Day Moving Average is calculated to be -15.40%.
Shares Statistics:
According to the various share statistics, RXRX traded on average about 43.40M shares per day over the past 3-months and 27089050 shares per day over the past 10 days. A total of 485.21M shares are outstanding, with a floating share count of 431.61M. Insiders hold about 17.07% of the company’s shares, while institutions hold 48.82% stake in the company. Shares short for RXRX as of 1764288000 were 151875532 with a Short Ratio of 3.50, compared to 1761868800 on 128586047. Therefore, it implies a Short% of Shares Outstanding of 151875532 and a Short% of Float of 30.91.
Earnings Estimates
Current recommendations for the stock of the company come from 6.0 analysts. The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.19 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.48 and -$1.73 for the fiscal current year, implying an average EPS of -$1.61. EPS for the following year is -$1.2, with 8.0 analysts recommending between -$0.63 and -$1.41.
Revenue Estimates
According to 7 analysts,. The current quarter’s revenue is expected to be $24.59M. It ranges from a high estimate of $46.4M to a low estimate of $17.1M. As of. The current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $4.55MFor the next quarter, 7 analysts are estimating revenue of $16.28M. There is a high estimate of $20.2M for the next quarter, whereas the lowest estimate is $10M.
A total of 9 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $85.5M, while the lowest revenue estimate was $48.35M, resulting in an average revenue estimate of $61.61M. In the same quarter a year ago, actual revenue was $58.84MBased on 9 analysts’ estimates, the company’s revenue will be $82.66M in the next fiscal year. The high estimate is $110.62M and the low estimate is $61.1M.
